Korea’s Celltrion Expects Price Of Remsima Biosimilar To Be 70% Of Remicade
This article was originally published in The Pink Sheet Daily
Executive Summary
Celltrion expects Korea’s National Health Insurance to cover Remsima and to start sales in the third quarter.